Latest news with #MichaelW.Freeman
Business Insider
10-07-2025
- Business
- Business Insider
Raymond James Remains a Buy on Vitalhub (VHI)
In a report released today, Michael W. Freeman from Raymond James maintained a Buy rating on Vitalhub, with a price target of C$14.50. The company's shares closed today at C$12.33. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, W. Freeman is a 3-star analyst with an average return of 5.9% and a 52.63% success rate. W. Freeman covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, NervGen Pharma, and Vitalhub. Vitalhub has an analyst consensus of Strong Buy, with a price target consensus of C$14.10, a 14.36% upside from current levels. In a report released yesterday, Scotiabank also maintained a Buy rating on the stock with a C$15.00 price target. The company has a one-year high of C$12.72 and a one-year low of C$6.74. Currently, Vitalhub has an average volume of 103.6K.
Business Insider
11-06-2025
- Business
- Business Insider
Wave Life Sciences (WVE) Initiated with a Buy at Raymond James
Raymond James analyst Michael W. Freeman initiated coverage with a Buy rating on Wave Life Sciences (WVE – Research Report) today and set a price target of $14.00. The company's shares closed today at $7.23. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter W. Freeman covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, MCI Onehealth Technologies, Inc. Class A, and WELL Health Technologies Corp. According to TipRanks, W. Freeman has an average return of -0.6% and a 43.75% success rate on recommended stocks. Wave Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $19.30, a 166.94% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $22.00 price target.
